Catalyst Calendar
Scope

Mon, Jun 22, 2026

1 updates
ENTX
8:30 AM

Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis

The planned Phase 3 trial in approximately 750 postmenopausal women with osteoporosis, with a primary endpoint of total hip bone mineral density (BMD) at Month 12, would support Entera’s plan to submit a New Drug Application (NDA) for EB613 Entera expects to submit its NDA for EB613 based on

enterabio.com

Tue, Jun 16, 2026

1 updates

Mon, Jun 15, 2026

1 updates
ENTX
8:45 AM

ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)

The pharmacokinetic (PK) and pharmacodynamic (PD) profiles of single tablet EB613, multi-tablet EB613 and Forteo® reported for the first time as an oral presentation at ENDO 2026 Single tablet EB613 achieved a comparable PK/PD profile to Forteo® and multi-tablet EB613, which was evaluated in

Presentation / Abstract • Phase 1ENDO 2026 Late-Breaking Oral Presentation Mon, Jun 15, 2026enterabio.com

Thu, May 28, 2026

1 updates
ENTX
8:50 AM

Entera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation

TEL AVIV, May 28, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that multiple abstracts across its oral peptide pipeline have been accepted for presentation at ENDO 2026, the annual meeting of the

Presentation / Abstract • Phase 2Late-breaking oral presentation Sun, Jun 14, 2026, 3:30 PM CTenterabio.com

Fri, May 8, 2026

1 updates

Tue, Apr 14, 2026

1 updates